GRACE MENSAH: Open Payments
NPI 1932988680 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,396 in 126 payments from 17 companies in 2025. Trend: 2023 $734 · 2024 $2,982 · 2025 $2,396
Food & beverage: $2,295Education: $101
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $348 |
| Otsuka America Pharmaceutical, Inc. | 23 | $299 |
| Teva Pharmaceuticals USA, Inc. | 8 | $265 |
| Neurocrine BioSciences, Inc. | 7 | $263 |
| ABBVIE INC. | 30 | $254 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $223 |
| Vanda Pharmaceuticals Inc. | 8 | $140 |
| Alkermes, Inc. | 10 | $122 |
| E.R. Squibb & Sons, L.L.C. | 5 | $108 |
| Axsome Therapeutics, Inc. | 5 | $99 |
Products named: INGREZZA, VRAYLAR, INVEGA SUSTENNA, CAPLYTA, REXULTI, FANAPT, AUSTEDO XR, COBENFY.
Industry payments across ID — which companies pay providers there.
